An interventional study of Wild Thyme extract and Placebo in Overweight and Obesity, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 388 studies in Obesity with a site in Spain — 93 open to participants now, 132 under way, 43 of them phase 3. Obesity · Spain.
Among the 388 studies in Obesity with a site in Spain, this one is the 251st largest by planned enrollment of the 330 interventional ones that give a count, is one of 41 that started in 2026, is one of 220 with no phase, reaches primary completion later than 73 of the 131 other live ones, and was the 381st registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →93 of the 388 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Brazil and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Belgium and 7 more countries
Ages 18+
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
388 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 79 · Phase 4 7
First in 2001; this study’s year is marked. 41 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 53 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 122 across the 330 interventional studies, 128 across the 57 observational. Of the 208 that completed or were terminated, 26 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 388 have an industry lead sponsor. The 10 most frequent:
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Spain that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07332273Phase 3Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
Add all 33 to your calendar (.ics) → With an account.
Among the 388 studies in Obesity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Overweight and obesity are characterized by excessive or abnormal adiposity and are associated with an increased risk of metabolic dysfunction, chronic low-grade inflammation, and several chronic diseases. While overweight is not classified as a disease in itself, it represents an early stage in the continuum of excess adiposity and is associated with an increased risk of progression to obesity and the development of obesity-related metabolic complications. Therefore, early intervention during the overweight stage may represent a critical opportunity to prevent or delay disease progression to obesity. Increasing evidence indicates that the gut microbiome plays an important role in metabolic homeostasis and may contribute to the development and progression of overweight and obesity through interactions with host metabolism, intestinal barrier function, immune responses, and microbial-derived metabolites.
This randomized, double-blind, placebo-controlled clinical trial will evaluate whether daily supplementation with a chemically characterized wild thyme (Thymus serpyllum L.) extract for 12 weeks can improve body weight and obesity- and overweight-related anthropometric, metabolic, and inflammatory parameters and modulate the gut microbiome in adults with overweight or obesity. Participants will be randomly assigned in a 1:1 ratio to receive either wild thyme extract or a matching placebo. The primary objective is to evaluate the effect of the intervention on change in body weight after 12 weeks of treatment. Secondary objectives include evaluating changes in body composition, waist circumference, metabolic parameters, inflammatory biomarkers, and intestinal microbiome composition. The study will also investigate whether baseline gut microbiome characteristics or changes in the gut microbiome are associated with the clinical response to treatment, with the aim of identifying potential microbiome-based biomarkers of response. By targeting individuals across the spectrum from overweight to obesity, this study aims to explore whether early intervention in excess adiposity may provide an opportunity to improve metabolic health and potentially reduce progression toward more severe obesity and associated complications.
Overweight and obesity are characterized by excessive or abnormal adiposity and are associated with alterations in metabolic homeostasis, chronic low-grade inflammation, and an increased risk of developing several chronic diseases. Obesity results from complex interactions among genetic, metabolic, behavioral, environmental, and socioeconomic factors. It is associated with an increased risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, and other obesity-related complications. Although overweight is not considered a disease in itself, it represents an early stage in the continuum of excess adiposity and is associated with an increased risk of progression to obesity and the development of metabolic complications. This stage may therefore represent an important window of opportunity for early intervention. Addressing excess adiposity before the development of established obesity may help prevent or delay its progression and reduce the subsequent burden of obesity-related metabolic alterations. Consequently, interventions that can be implemented at both the overweight and obesity stages may have potential clinical relevance for improving metabolic health and limiting progression toward more severe adiposity. Current approaches to the management of excess adiposity include lifestyle modification, dietary intervention, physical activity, pharmacological treatment, and, in selected individuals with obesity, bariatric procedures. However, achieving and maintaining clinically meaningful improvements in body weight and metabolic health remains challenging. Therefore, complementary strategies capable of simultaneously influencing body weight, metabolic health, inflammation, and intestinal homeostasis can be crucial, particularly when they are implemented at an early stage of excess adiposity. The gut microbiome has emerged as an important regulator of host metabolism and energy homeostasis. Alterations in intestinal microbial composition and function have been associated with overweight and obesity and may influence energy metabolism, intestinal permeability, bile acid metabolism, short-chain fatty acid production, immune regulation, and systemic inflammatory responses. These alterations may occur along the continuum of increasing adiposity and could contribute to the transition from metabolic health toward obesity-associated metabolic dysfunction. Consequently, modulation of the intestinal microbiome represents a potential complementary strategy for improving metabolic health in individuals with overweight or obesity. Wild thyme (Thymus serpyllum L.) is a plant used in Traditional Medicine that contains bioactive compounds, including phenolic compounds and other phytochemicals with antioxidant and anti-inflammatory properties. Previous experimental studies have demonstrated beneficial effects of Thymus serpyllum extract in models of diet-induced obesity, including attenuation of the inflammatory state and modulation of obesity-associated gut dysbiosis. These findings support the potential role of this botanical extract as a complementary intervention for improving metabolic and intestinal homeostasis in individuals with excess adiposity. The present study will extend this research by specifically investigating adults with overweight or obesity and evaluating the potential effects of the intervention on body weight, anthropometric parameters, metabolic health, inflammation, and the intestinal microbiome. Participants will be randomized in a 1:1 ratio to receive either a chemically characterized Thymus serpyllum extract or a matching placebo for 12 weeks. The intervention will be administered orally once daily in capsule form. Anthropometric, body composition, metabolic, and inflammatory parameters will be assessed at baseline and following the 12-week intervention. Fecal samples will be collected at predefined time points for characterization of the intestinal microbiome using metagenomic sequencing. The primary hypothesis is that daily supplementation with Thymus serpyllum extract for 12 weeks will result in a greater reduction in body weight compared with placebo in adults with overweight or obesity. Secondary hypotheses are that the intervention may improve body composition, waist circumference, metabolic parameters, and obesity- and overweight-associated inflammatory alterations and may favorably modulate the composition and functional characteristics of the intestinal microbiome. An additional objective is to investigate whether baseline microbiome characteristics and changes in microbiome composition are associated with the magnitude of clinical response, potentially identifying microbiome-based biomarkers capable of predicting response to the intervention. By including individuals with both overweight and obesity, the study will evaluate the potential effects of the intervention across different stages of excess adiposity. Particular interest will be placed on determining whether intervention at the overweight stage, before the establishment of obesity, may represent a relevant opportunity to improve metabolic health and potentially reduce progression toward obesity and associated complications.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's planned enrollment of 53 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: 1. Adults aged 18 to 75 years at the time of screening.
2. (BMI) ≥25.0 kg/m² at screening.
3. Participants with overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥30.0 kg/m²).
4. Stable body weight during the predefined period before screening.
5. Willingness to maintain usual dietary and physical activity habits throughout the intervention period.
6. Ability and willingness to provide fecal samples at the predefined study time points.
7. Ability to comply with study procedures and intervention requirements.
8. Ability to understand the study procedures and provide written .
Exclusion Criteria: 1. Systemic antibiotic treatment within the predefined period before enrollment.
2. Presence of established or clinically unstable cardiovascular disease. 3. Pregnancy or breastfeeding. 4. Clinical diagnosis of inflammatory bowel disease. 5. Clinical diagnosis of celiac disease. 6. Major gastrointestinal disease that may interfere with study outcomes. 7. Previous bariatric surgery.
8. Current participation in another interventional clinical trial.
9. Use of drugs within the predefined .
10. Known allergy or to Thymus species or any component of the study product or placebo.
11. Use of probiotics, prebiotics, synbiotics, or other microbiome-modulating supplements during the predefined washout period.
12. Any medical condition that, in the investigator's opinion, may interfere with participant safety, study compliance, interpretation of results, or completion of study procedures.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the experimental arm will receive a chemically characterized wild thyme (Thymus serpyllum L.) extract at a total daily dose of 600 mg, administered orally in capsule form once daily for 12 weeks.
Dietary Supplement: Wild Thyme extract
Participants assigned to the placebo arm will receive matching placebo capsules containing microcrystalline cellulose at an equivalent daily administration schedule for 12 weeks.
Dietary Supplement: Placebo
Chemically characterized Thymus serpyllum L. extract administered orally at a total daily dose of 600 mg in capsule form once daily for 12 weeks.
Microcrystalline cellulose, 600 mg/day, administered orally in matching capsules once daily for 12 weeks.
Change in body mass index (BMI) from baseline to week 12.
Change in body mass index (BMI) following a 12-week intervention with a chemically characterized Thymus serpyllum L. extract in adults with overweight or obesity. BMI will be calculated as body weight in kilograms divided by height in meters squared.
Time frame: Baseline to week 12
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
Of 3,685 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.
Counting every sponsor, half of 3,848 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental